PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [18F]DPA714

Wei Hu, Donghui Pan, Yalin Wang, Weiqi Bao, Chuantao Zuo, Yihui Guan, Fengchun Hua, Min Yang, Jun ZhaoFrontiers in Neuroscience 2020 · DOI

Abstract

Neuroinflammation, characterized by microglial activation and overexpression of the 18-kDa translocator protein (TSPO), is a hallmark of Alzheimer's disease (AD). This study optimized the synthesis of the second-generation PET tracer $[^{18}F]DPA714$ and utilized it to dynamically monitor neuroinflammation in the APP/PS1 mouse model across various ages (6–16 months). Results demonstrated that significant microglial activation emerges at 12–13 months, correlating strongly with histological markers. These findings highlight the potential of $[^{18}F]DPA714$ PET imaging for identifying optimal therapeutic windows for anti-inflammatory interventions in AD.

Introduction

Alzheimer's disease (AD) pathogenesis involves not only amyloid-beta plaques and tau tangles but also a robust neuroinflammatory response driven by microglia, the brain's immune cells. Monitoring this activation is essential for understanding disease progression and evaluating treatments. TSPO is a validated biomarker for microglial activation, but early tracers like $[^{11}C]PK11195$ suffer from short half-lives and high non-specific binding. $[^{18}F]DPA714$ offers improved specificity and a longer half-life, yet its longitudinal performance in AD models required further validation and synthesis optimization.

Methods

Radiochemistry Optimization

The synthesis of $[^{18}F]DPA714$ was optimized by varying precursor dosage, temperature, and reaction time. The crude mixture was purified using semi-preparative reversed-phase HPLC to ensure high radiochemical purity.

Longitudinal Imaging and Validation

APP/PS1 and Wild-type (Wt) mice were scanned using micro-PET at 6–7, 9–10, 12–13, and 15–16 months. PET images were co-registered with MRI templates to analyze Volumes of Interest (VOIs) in the cortex and hippocampus. Tracer specificity was confirmed via blocking studies with the TSPO antagonist PK11195, and PET signals were correlated with Iba-1 and TSPO immunofluorescence staining.

Results

Synthesis and Purity

Optimal radiochemical yield (42.3 ± 5.1%, non-decay corrected) was achieved using 2 mg of precursor dissolved in 300 µl acetonitrile at 105°C for 10 minutes.

Extracted figure from page 1 of PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [18F]DPA714

The final product exhibited exceptional radiochemical purity (99.9%), as confirmed by radio-HPLC analysis, which showed a single sharp peak corresponding to the tracer.

Extracted figure from page 4 of PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [18F]DPA714

Longitudinal Monitoring

No significant differences in tracer uptake were observed between AD and control groups at 6–10 months. However, at 12–13 months, APP/PS1 mice showed significantly higher uptake in the cortex (2.77 ± 0.13 vs. 1.93 ± 0.32, p = 0.0014) and hippocampus (3.33 ± 0.10 vs. 2.10 ± 0.35, p = 0.0008) compared to controls. This elevation persisted into the 15–16 month bracket.

Discussion and Conclusion

The study identifies a critical "flare-up" point for neuroinflammation at approximately 12 months in the APP/PS1 model. The high correlation between PET signal and histology ($r^2$ between 0.76 and 0.88) validates $[^{18}F]DPA714$ as a reliable tool for tracking microglial density. While human application must account for TSPO genetic polymorphisms, this optimized mouse protocol provides a robust framework for testing anti-inflammatory drug efficacy in preclinical stages.

$[^{18}F]DPA714$ PET imaging effectively monitors the dynamic progression of neuroinflammation in AD models. By pinpointing the onset of significant microglial activation, this approach facilitates the identification of optimal timing for anti-inflammatory therapies.

Summary updated

Abstract

<b>Background:</b> In the pathogenesis of Alzheimer's disease (AD), microglia play an increasingly important role. Molecular imaging of neuroinflammatory targeting microglia activation and the high expression of 18-kDa translocator protein (TSPO) has become a hot topic of research in recent years. Dynamic monitoring neuroinflammation is crucial for discovering the best time point of anti-inflammatory therapy. Motivated by this, Positron emission tomography (PET) imaging in an APP/PS1 mouse model of AD, using <sup>18</sup>F-labeled DPA-714 to monitor microglia activation and neuroinflammation, were performed in this paper. <b>Methods:</b> We prepared [<sup>18</sup>F]DPA714 and tested the biological characteristics of the molecular probe in normal mice. To obtain a higher radiochemical yield, we improved the [<sup>18</sup>F]-fluorination conditions in the precursor dosage, reaction temperature, and synthesis time. We performed [<sup>18</sup>F]DPA714 PET scanning on APP/PS1 mice at 6-7, 9-10, 12-13, and 15-16 months of age, respectively. The same experiments were conducted in Wild-type (Wt) mice as a control. Referring to the [<sup>18</sup>F]DPA714 concentrated situation in the brain, we performed blocking experiments with PK11195 (1 mg/kg) in 12-13-months-old APP/PS1 mice to confirm the specificity of [<sup>18</sup>F]DPA714 for TSPO in the APP/PS1 mice. Reconstructed brain PET images, fused with the Magnetic Resonance Imaging (MRI) template atlas, and the volumes of interests (VOIs) of the hippocampus and cortex were determined. The distribution of [<sup>18</sup>F]DPA714 in the brain tissues of 15-16-months-old APP/PS1 and Wt mice were studied by immunofluorescence staining. <b>Results:</b> Through the reaction of <sup>18</sup>F, with 2 mg precursor dissolved in 300 ul acetonitrile at 105°C for 10 min, we obtained the optimal radiochemical yield of 42.3 ± 5.1% (non-decay correction). Quantitative analysis of brain PET images showed that the [<sup>18</sup>F]DPA714 uptake in the cortex and hippocampus of 12-13-months-old APP/PS1 mice was higher than that of the control mice of the same age (cortex/muscle: 2.77 ± 0.13 vs. 1.93 ± 0.32, <i>p</i> = 0.0014; hippocampus/muscle: 3.33 ± 0.10 vs. 2.10 ± 0.35, <i>p</i> = 0.0008). The same significant difference was found between 15- and 16-months-old APP/PS1 mice (cortex/muscle: 2.64 ± 0.14 vs. 1.86 ± 0.52, p=0.0159; hippocampus/muscle: 2.89 ± 0.53 vs. 1.77 ± 0.48, <i>p</i> = 0.0050). Immunofluorescence staining showed that the activation of microglia and the level of TSPO expression in the cortex and hippocampus of APP/PS1 mice were significantly higher than Wt mice. <b>Conclusion:</b> [<sup>18</sup>F]DPA714, a molecular probe for targeting TSPO, showed great potential in monitoring microglia activation and neuroinflammation, which can be helpful in discovering the best time point for anti-inflammatory therapy in AD.
BibTeX
@inproceedings{hu2020pet,
  author = {Wei Hu and Donghui Pan and Yalin Wang and Weiqi Bao and Chuantao Zuo and Yihui Guan and Fengchun Hua and Min Yang and Jun Zhao},
  title = {{PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [18F]DPA714}},
  booktitle = {Frontiers in Neuroscience},
  year = {2020},
  doi = {10.3389/fnins.2020.00810},
}
Figure